NASDAQ · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · SMALL CAP
Natural Alternatives International Inc. NAII
15 fiscal years on record · USD · FY2024 reported · SEC filings only
In brief
What this company does
Written from the business description in NATURAL ALTERNATIVES INTERNATIONAL INC's annual report to the U.S. Securities and Exchange Commission, filed 23 September 2025. Every sentence was checked against that document before publication.
Growth
USD 129.9M
Revenue, FY2024 · full 15-year series below
Revenue $M
Net income $M
FY2024 · Revenue 129.9 · Net income -13.6
Compound annual growth
Revenue compounded at +1.8% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−10 cents
lost on every revenue dollar
Operating margin
Net margin
FY2024 · Operating -6.7% · Net -10.5%
ROE
FY2024 · ROE -18.0%
Each USD of equity lost 18 cents this year.
The 15-year record
15 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Operating income $B | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBITDA $B | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Income tax $B | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 |
| Net income $B | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Free cash flow $B | 0.0 | −0.0 | −0.0 | −0.0 | 0.0 | −0.0 | 0.0 | −0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 |
| EPS, diluted $ | −2.28 | −1.23 | 0.43 | 1.74 | 1.69 | −0.25 | 0.92 | 0.73 | 1.09 | 1.44 | 0.49 | 0.29 | 0.23 | 0.59 | 0.71 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −18.0 | −8.4 | 2.8 | 12.7 | 14.2 | −2.2 | 9.1 | 7.8 | 12.6 | 19.6 | 7.8 | 4.8 | 3.9 | 11.0 | 14.3 |
| Shares out B | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 75 reconciliationsAUDITED
Reconciled in 15 of 19 fiscal years. 20 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityMedicinal Chemicals & Botanical Products
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsJune 30
SEC categorysmaller reporting company
Data on record since2010